EUVIMEDEUVIMED entdecken
Crossref

Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis

Hidetaka Hiyama iD, Naoya Arichika, Minoru Okada, Noriyuki Koyama, Tomonori Tahara, Junpei Haruta

The Journal of Pharmacology and Experimental Therapeutics · 2023-07 · 386 (1) · 45-55

DOI: 10.1124/jpet.123.001609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-07. Verfasst von Hidetaka Hiyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ako Research Institute, Otsuka Pharmaceutical Co., Ltd., Hyogo, Japan (H.H., N.A., M.O., J.H.) and Tokushima Research Institute, Otsuka Pharmaceutica…. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Dermatitis, Atopic, Dermatitis, Allergic Contact. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsDermatitis, AtopicDermatitis, Allergic ContactHumansMiceRatsAnimalsSwineLeukocytes, MononuclearTumor Necrosis Factor-alphaBenzamides

Substanzen

Phosphodiesterase 4 InhibitorsTumor Necrosis Factor-alphadifamilastBenzamides

Autor:innen und Institutionen

  • Ako Research Institute, Otsuka Pharmaceutical Co., Ltd., Hyogo, Japan (H.H., N.A., M.O., J.H.) and Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan (N.K., T.T.) Hiyama.Hidetaka@otsuka.jp.
  • Ako Research Institute, Otsuka Pharmaceutical Co., Ltd., Hyogo, Japan (H.H., N.A., M.O., J.H.) and Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan (N.K., T.T.).

ORCID-Profile: Hidetaka Hiyama

Zitieren

APA

Hiyama, H., Arichika, N., Okada, M., Koyama, N., Tahara, T., & Haruta, J. (2023). Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis. The Journal of Pharmacology and Experimental Therapeutics, 386(1), 45-55. https://doi.org/10.1124/jpet.123.001609

Vancouver

Hiyama H, Arichika N, Okada M, Koyama N, Tahara T, Haruta J. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis. The Journal of Pharmacology and Experimental Therapeutics. 2023;386(1):45-55. doi:10.1124/jpet.123.001609

BibTeX
@article{Hiyama2023,
  author = {Hiyama, Hidetaka and Arichika, Naoya and Okada, Minoru and Koyama, Noriyuki and Tahara, Tomonori and Haruta, Junpei},
  title = {Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  volume = {386},
  number = {1},
  pages = {45--55},
  doi = {10.1124/jpet.123.001609}
}
Kostenlos starten →